Brivaracetam for the treatment of epilepsy.
Bethesda, United States. In Expert Opin Pharmacother, Feb 2016
Levetiracetam is an effective antiepileptic drug (AED) postulated to act by binding to synaptic vesicle protein 2A.
Actions of Bisphenol A and Bisphenol S on the Reproductive Neuroendocrine System During Early Development in Zebrafish.
Shanghai, China. In Endocrinology, Jan 2016
Environmentally relevant, low levels of BPA exposure during development led to advanced hatching time, increased numbers of Gonadotropin-Releasing Hormone 3 (GnRH3) neurons in both terminal nerve and hypothalamus, increased expression of reproduction-related genes (kiss1, kiss1r, gnrh3, lhβ, fshβ, and erα) and a marker for synaptic transmission (sv2).
Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.
Napoli, Italy. In Expert Opin Pharmacother, 2014
Furthermore, for some of these (e.g., lacosamide and eslicarbazepine) data are already available from post-marketing studies while brivaracetam acting on SV2A like levetiracetam might have the same potential effectiveness with the possibility to be more efficacious considering its ability to inhibit voltage gated sodium channels; finally, perampanel and retigabine are very effective drugs in animal models of TLE.
Brivaracetam for the treatment of epilepsy in adults.
London, United Kingdom. In Expert Rev Neurother, 2014
Brivaracetam (BRV) is a new antiepileptic drug structurally related to levetiracetam but with a 15 to 30-fold increased affinity for the same molecular target, namely the SV2A ligand.
Structural basis for recognition of synaptic vesicle protein 2C by botulinum neurotoxin A.
China. In Nature, 2014
Two types of BoNT/A receptor have been identified, both of which are required for BoNT/A toxicity and are therefore likely to cooperate with each other: gangliosides and members of the synaptic vesicle glycoprotein 2 (SV2) family, which are putative transporter proteins that are predicted to have 12 transmembrane domains, associate with the receptor-binding domain of the toxin.
Structure activity relationships of novel antiepileptic drugs.
Los Angeles, United States. In Curr Med Chem, 2013
The synaptic vesicle glycoprotein 2A (SV2A), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) and voltage-gated potassium channels (KCNQ2/Q3) are clinically validated as new molecular targets for epilepsy.